Your Health, We Care
Cholangiocarcinoma: The most common adverse reactions (incidence ≥ 20%) are hyperphosphatemia, alopecia, diarrhea, nail toxicity, fatigue, dysgeusia, nausea, constipation, stomatitis, dry eye, dry mouth, decreased appetite, vomiting, arthralgia, abdominal pain, hypophosphatemia, back pain, and dry skin.
Myeloid/lymphoid neoplasms with FGFR1 rearrangement: The most common (≥ 20%) adverse reactions are hyperphosphatemia, nail toxicity, alopecia, stomatitis, diarrhea, dry eye, fatigue, rash, abdominal pain, anemia, constipation, dry mouth, epistaxis, serous retinal detachment, extremity pain, decreased appetite, dry skin, dyspepsia, back pain, nausea, blurred vision, peripheral edema, and dizziness.
from FDA，2024.06
In the medical field, each drug comes with its specific therapeutic effects and ···【more】
Release date：2024-12-25Recommended：139
As an emerging drug, Selpercatinib has shown potential in the treatment of speci···【more】
Release date：2024-12-25Recommended：101
Selpercatinib blocks tumor growth and spread by inhibiting the kinase activity o···【more】
Release date：2024-08-16Recommended：129
Selpercatinib is an innovative RET inhibitor specifically designed to treat canc···【more】
Release date：2024-08-16Recommended：134
Selpercatinib is a highly selective RET inhibitor that inhibits the growth of tu···【more】
Release date：2024-08-16Recommended：118
